header logo image


Page 986«..1020..985986987988..1,0001,010..»

Arthritis drug shows promise in combatting protein that causes aortic valve stenosis – Cardiovascular Business

June 15th, 2017 9:44 pm

Development of a drug to help those suffering from rheumatoid arthritis may prove to be quite a happy accident for aging individuals with hardening heart valves. Researchers from Vanderbilt University announced promising results in examining a monoclonal antibodys ability to combat aortic valve stenosis.

The results, published June 12 in Circulation, could be an important step toward fighting the condition that affects a quarter of Americans over the age of 65, who previously only had surgical replacement of valves as an option.

Very elderly patients bodies cant handle that, said first author Cyndi Clark, research assistant professor of biomedical engineering at Vanderbilt. I hope to see an earlier treatment option available within the next decade.

The drug, known as SYN0012, appeared to bind to cadherin-11 (CDH-11), a protein that causes the hardening of valve tissue.

The antibody we're working with blocks fibroblasts from becoming the active type that leads to disease. It keeps them from becoming inflamed, said W. David Merryman, associate professor of biomedical engineering at Vanderbilt. "We believe there is potential for using this drug at the first sign of valve disease to prevent the progression. You likely cannot reverse the damage, but we believe the drug can prevent it."

The drug is in human clinical trials for treatment of rheumatoid arthritis. After those are complete, Merryman hopes to gain permission to run clinical trials for uses in heart valve disease. His work is funded by a $5.3 million award from the National Heart, Lung and Blood Institute.

More:
Arthritis drug shows promise in combatting protein that causes aortic valve stenosis - Cardiovascular Business

Read More...

New Law Opens Door for Stem Cell Therapy in Texas – Spectrum News

June 15th, 2017 9:43 pm

AUSTIN, Texas -- The legal battle to get patients access to stem cell therapy in Texas is closer to reality.

Gov. Greg Abbott signed such legislation into law this week, and itmeans some patients will be heading into uncharted medical territory.

Come Sept. 1, patients with terminal illnesses or severe chronic diseases will be allowed to access experimental stem cell treatments in Texas.

MORE |Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments

Currently, mostpatients who want stem cell therapy have to travel outside the United States to do it, and stem cell re-injections are only allowed here within a 24-hour window.

"This is going to protect patient health, and provide for the treatments to be done here locally at home," saidMike Byrom, the Chief Science Officer at Austin stem cell bankBioEden.

Byrom said the new lawwill keep patients in the country, and will provide renewed hope for those with serious ailments.

This hope resulted in anemotional fight this session.

Texas State Rep. Drew Springer, R-Gainesville, gave an impassioned speech for the legislation as the deadline to read new bills approached, urging lawmakers to keep it from dying.

"I'll be damned if we don't get the chance tonight to hear the very next bill that opens up the doors of medical science," saidSpringer, whose wife is wheelchair-bound."It might give somebody like my wife a chance to walk."

But not everyone's convinced this is the right way to go.

"We want access for patients to the best drugs, but we think they ought to go through the FDA approval process," saidTexans for Cures Chairman David Bales.

Bales was one of the few people who testified against the bill. While he supports more stem cell research,hearguesthe state should fund it, rather than letting for-profit businesses lead the way.

"You run the risk of medical fraud because a lot of these guys, a lot of these patients, are paying a lot of money, to physicians and drug manufacturers who haven't gone through the right process,"Balessaid.

Patients who will be participating in stem cell therapy procedures will give up their right to take legal action if something goes wrong.

---

Join the Discussion:

Follow Capital Tonight Texas on Facebook & Twitter

Keep the conversation going on our political blog: Capital Roundup .

Continue reading here:
New Law Opens Door for Stem Cell Therapy in Texas - Spectrum News

Read More...

Milestones in living with blindness in the modern day | A Different … – Walla Walla Union-Bulletin

June 15th, 2017 1:45 am

Have you ever thought about how people in the modern day have dealt with being blind?

I did some research and learned a lot. Following are some bits of information you may find interesting.

1829: Louis Braille publishes his system of writing the French language. Its 1837 revision was the first modern binary writing form developed.

1832: The Perkins School for the Blind in Boston admitted its first two students sisters Sophia and Abbey Carter.

Perkins manufactures its own Perkins Brailer, which is used to print embossed, tactile books for the blind.

1860: Simon Pollak demonstrates the use of Braille at the Missouri School for the Blind.

1861: Helen Adams Keller is born in Tuscumbia, Ala.

1864: The enabling act giving the Columbia Institution for the Deaf and Blind the authority to confer college degrees is signed by President Abraham Lincoln, making it the first college in the world expressly established for people with disabilities. Columbia University, its name later changed to Gallaudet University, is in Washington, D.C.

1878: Joel W. Smith presents his Modified Braille to the American Association of Instructors of the Blind. The association rejects his system, continuing to endorse instead New York Point, which blind readers complain is more difficult to read and write.

What followed was a War of the Dots in which blind advocates for the most part preferred Modified Braille, while sighted teachers and administrators, who controlled the funds for transcribing, wanted New York Braille.

1909: The New York Public School System adopts Modified or American Braille for use in its classes for blind children, after public hearings in which blind advocates call for abandoning New York Point.

1909: The first folding wheelchairs are introduced for people with mobility disabilities.

1921: The American Foundation for the Blind is founded. Helen Keller is its principal fundraiser.

1929: Seeing Eye establishes the first guide dog school for blind people in the United States. Today, this well-known guide dog school is in Morristown, N.J.

1932: The Treaty of London standardizes American and English Braille.

1933: Franklin Delano Roosevelt, the first seriously physically disabled person ever to be elected as a head of government, is sworn into office as president of the United States. He chooses to minimize his disability in response to the ableism of the electorate.

1936: Passage of the Randolph Sheppard Act establishes a federal program for employing blind vendors at stands in the lobbies of federal office buildings.

1937: Herbert A. Everest and Harry C. Jennings patent a design for a folding wheelchair with an X-frame that can be packed into a car trunk.

1940: The National Federation of the Blind is formed in Wilkes-Barre, Pa., by Jacobus Broek and other blind advocates. Among other reforms, it pushes for white cane laws and input by blind people into programs for blind clients.

Since 1942: Guide Dogs for the Blind (GDB) has created partnerships between people, dogs and communities. With client services and a network of instructors, puppy raisers, donors and volunteers, the agency prepares highly qualified guide dogs to serve and empower individuals who are blind or have low vision throughout the United States and Canada.

All services for GDBs clients are provided free of charge, including personalized training and extensive post-graduation support, plus financial assistance for veterinary care, if needed. GDB has two campuses in San Rafael, Calif., and Boring, Ore.

1943: Congress passes the Vocational Rehabilitation Amendments, known as the LaFollette-Barden Act, adding physical rehabilitation to the goals of federally funded vocational rehabilitation programs and providing funding for certain health care services.

1945: The Blinded Veterans Association is formed in Avon, Conn. Its mission is to promote the welfare of blinded veterans so that, notwithstanding their disabilities, they may take their rightful place in the community and work with fellow citizens toward the creation of a peaceful world.

1961: The American Council of the Blind is formally organized. ACB strives to increase the independence, security, equality of opportunity and quality of life, for all blind and visually impaired people.

1963: John Hessler joins Ed Roberts at the University of California at Berkeley, other disabled students follow. Together they form the Rolling Quads to advocate for greater access on campus and in the surrounding community.

1968: The Architectural Barriers Act is passed by Congress, mandating federally constructed buildings and facilities be accessible to all people.

The ABA requires access for everyone whether blind or with any other disability to have access into any facilities designed, built, altered or leased with federal funds.

This marks one of the first efforts to ensure access to the constructed environment for all people.

Blindness or visual impairment can have a profound impact on your life, but you are still in control there is an abundance of information to help you.

Ernie Jones, a registered nurse who retired due to vision loss, can be reached at 529-9252 or eajsr37@outlook.com.

Follow this link:
Milestones in living with blindness in the modern day | A Different ... - Walla Walla Union-Bulletin

Read More...

Prevent Blindness Works to Educate the Public on the Dangers of … – Benzinga

June 15th, 2017 1:45 am

Prevent Blindness Provides Alternative Ideas on Ways Families Can Celebrate Independence Day Safely

CHICAGO (PRWEB) June 14, 2017

The U.S. Consumer Product Safety Commission (CPSC), estimated that injuries from fireworks sent 8,000 Americans to the emergency room over the Fourth of July holiday. The latest CPSC annual report stated that forty-two percent of the estimated emergency department-treated, fireworks-related injuries were to individuals younger than 20 years of age. Sadly, the CPSC also reported 11 non-occupational fireworks-related deaths.

The American Pyrotechnics Association states that Delaware, Massachusetts and New Jersey are the only states that ban all consumer fireworks. Fireworks laws vary from state to state and sometimes, within different counties.

A recent study, "Effect of Fireworks Laws on Pediatric Fireworks-Related Burn Injuries," published in the Journal of Burn Care & Research, concluded that the relaxing of fireworks laws in the United States has had a dramatic effect on the severity of the related injuries, resulting in more inpatient admissions and longer length of stay in the hospital.

Yet despite the thousands of injuries and consumer firework-related deaths, some state government representatives are moving to lift restrictions on consumer fireworks.

In fact, in Iowa, a new law enacted in April allows retail sales of consumer fireworks in permanent buildings between June 1 and July 8, and again between Dec. 10 and Jan. 3.

As a public health-based organization, Prevent Blindness supports the development and enforcement of bans on the importation, sale and use of all fireworks and sparklers, except those used in authorized public displays by competent licensed operators. The national non-profit group, including its affiliates, works with leading organizations to educate the public on the dangers of consumer fireworks and endorses legislation to help protect adults and children from needless injuries from fireworks.

The CPSC states that burns from fireworks are the most common injury to all parts of the body, except the eyes, where contusions, lacerations, and foreign bodies in the eyes occurred more frequently. According to the American Academy of Pediatrics, approximately one third of eye injuries from fireworks result in permanent blindness.

Prevent Blindness, the nation's oldest volunteer eye health and safety organization, offers alternatives to celebrate the holiday safely:

"The Fourth of July can still be fun without fireworks," said Hugh R. Parry, president and CEO of Prevent Blindness. "By attending only fireworks shows run by licensed professionals, and being vigilant, we can celebrate our nation's birthday with family and friends, not in the emergency room."

For more information on the dangers of fireworks, please call Prevent Blindness at (800) 331-2020, or visit preventblindness.org/prevent-eye-injuries-fireworks.

About Prevent Blindness Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at preventblindness.org or facebook.com/preventblindness.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14422232.htm

Read the original:
Prevent Blindness Works to Educate the Public on the Dangers of ... - Benzinga

Read More...

Biotechnology company opens mosquito factory in Lexington … – Lexington Herald Leader

June 15th, 2017 1:45 am

Lexington Herald Leader
Biotechnology company opens mosquito factory in Lexington ...
Lexington Herald Leader
A Lexington biotechnology company aimed at fighting mosquito-borne diseases such as the Zika virus opened a mosquito factory Friday on Malabu Drive.

and more »

Read the original:
Biotechnology company opens mosquito factory in Lexington ... - Lexington Herald Leader

Read More...

Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share – The Cerbat Gem

June 15th, 2017 1:45 am

NormanObserver.com
Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share
The Cerbat Gem
Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings of ($2.13) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Puma ...
Right After Earnings, The Intelligent Options Trade in Puma Biotechnology IncCML News
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at Stifel NicolausSports Perspectives
The Puma Biotechnology Inc (PBYI) Downgraded by Zacks Investment Research to HoldBangaloreWeekly
BBNS -Transcript Daily -Chaffey Breeze -SEC.gov
all 88 news articles »

See the rest here:
Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share - The Cerbat Gem

Read More...

Rheumatoid arthritis: Being overweight might NOT be a risk factor in … – Express.co.uk

June 15th, 2017 1:45 am

GETTY

The autoimmune condition is caused by the immune system attacking healthy body tissue.

However, researchers explored whether high body fat and large waist size were a risk factor.

In the study, presented this week to the Annual European Congress of Rheumatology 2017, they found no clear association between rheumatoid arthritis (RA) and being overweight or obese in men.

However, for women, being overweight or obese was linked to a higher likelihood of developing it.

GETTY

This conflicts with previous studies that found an association for both genders between rheumatoid arthritis and being overweight or obese.

This conflicts with previous studies that found an association for both genders.

Dr. Asta Linauskas, lead study author from University Hospital, Aarhus in Denmark, said: One possible explanation for these inconsistencies is that while BMI has been the preferred surrogate measure for being overweight in these studies, BMI only correlates modestly with total amount of body fat and does not accurately reflect fat distribution.

"Our results support an association between the risk of developing RA and three different criteria for being overweight or obese in women.

We believe RA should be included in the list of all the other medical conditions linked to obesity. It would certainly make sense for women with a family history of RA to try to avoid becoming overweight.

Getty

1 of 12

GETTY

In the study, they looked at 54,284 people - 52 per cent women - between the ages of 50 and 64 years at the time of recruitment between 1993 and 1997.

During a median follow up of 21 years, 283 women and 110 men developed RA.

The median time for onset of the condition was seven years.

In the data, a positive slope in women confirmed a direct relationship, but there was no such linear association in men.

GETTY

According to the NHS, other possible risk factors include genetics, hormones and smoking.

As well as joint pain, symptoms can include sweating, a poor appetite and weight loss.

The condition can be difficult to diagnose as many conditions cause joint stiffness and inflammation.

However, once diagnosed, treatment can be used to enable you still stay as active as possible.

Link:
Rheumatoid arthritis: Being overweight might NOT be a risk factor in ... - Express.co.uk

Read More...

‘Advances made in stem cell therapy in Asia far more than those made in US’ – The Hindu

June 15th, 2017 1:44 am
'Advances made in stem cell therapy in Asia far more than those made in US'
The Hindu
Indigenously developed therapeutic modules for neuro development disorders like autism have demonstrated a higher rate of recovery and improvement among sufferers, Nandini Gokulchandran, a Mumbai-based researcher in the field of stem cell therapy ...

Original post:
'Advances made in stem cell therapy in Asia far more than those made in US' - The Hindu

Read More...

Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments – Spectrum News

June 15th, 2017 1:44 am

AUSTIN, Texas -- Gov. Greg Abbott has signed a new law that allows terminally ill or those which chronic diseases receive stem cell treatments in Texas.

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, and is often patient's last hope for improvement.

Bone marrow transplant is the most widely used stem-cell therapy, and can often help those with multiple sclerosis and other diseases.

House Bill 810, which was introduced by Rep. Tan Parker, R-Flower Mound, passed in both the Texas House and Senate.

"It is easy to fall into the trap of viewing legislation as just words on a piece of paper," said Sen. Paul Bettencourt, R-Houston, the bill's sponsor in the Senate. "But for the many people who are ill with multiple sclerosis and other diseases that stem cell therapy has the hope of solving in our lifetime, I look at this bill, I look at the possibility of what can happen in the 21st Century, with Texas taking the lead on adult stem cell treatments and this bill has the potential to extend lives and make a difference for these patients."

The Texas Medical Board will be responsible for writing the rules for the treatment.

"Everyone has a zest for life. This adult stem cell treatment possibility gets government out of the way to let these new therapies flourish and give these patients hope for a future good quality of life," Bettencourt added.

The legislation takes effect Sept. 1.

-- Value of Stem Cell Therapy --

According to the National Institues of Health, stem cellshave the remarkable potential to develop into many different cell types in the body during early life and growth.

In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Doctors say stem cells are important for living organisms for many reasons.

In the 3- to 5-day-old embryo, called ablastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lungs, skin, sperm, eggs and other tissues.

In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease.

---

Join the Discussion:

Follow Spectrum News Austin on Facebook | Twitter | Instagram

Read the original post:
Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments - Spectrum News

Read More...

Family’s mission to raise profile of type one diabetes – BBC News

June 14th, 2017 12:48 am

BBC News
Family's mission to raise profile of type one diabetes
BBC News
The family of a teenager who died from type one diabetes has made it "their mission" to raise the profile of the condition. Peter Baldwin, 13, from Cardiff, died in 2015, just days after he was diagnosed. His family are working closely with Diabetes UK ...

and more »

Continued here:
Family's mission to raise profile of type one diabetes - BBC News

Read More...

Raceland boy to advocate diabetes research – Daily Comet

June 14th, 2017 12:48 am

By Garrett Ohlmeyer Staff Writer

An 11-year-old from Raceland will be joining about 160 other kids and celebrities in Washington, D.C., next month to advocate continued support of Type 1 diabetes research.

Rory Monier was diagnosed with Type 1 diabetes in November 2007 when he was just 2 years old.This fall, he will be a seventh-grader at Lockport Middle School, and he doesnt let his disease stop him from being a normal kid. Monier plays on a soccer team, plays drums in his middle school band and is involved in school clubs.

He said he was happy to be selected by the Juvenile Diabetes Research Foundation to represent those who have the disease and to share his family's story with Congress.

I want my congressman to know that kids battling Type 1 diabetes have a constant reminder that we have diabetes every time we eat or want to take part in activities, Monier said. We have daily schedules that are important in saving our lives.

The children and other delegates will share personal experiences and explain the daily struggles associated with living with the disease. The goal is to push for continued support of the Special Diabetes Program, which pays for research projects related to the disease. The program is set to expire Sept. 30.

Nine celebrities will join the children in the event. They include athletes and actors.

Type 1 diabetes is a condition that causes a person's pancreas to stop producing insulin, a hormone that enables people to gain energy from food. This happens when the immune system attacks and destroys cells in the pancreas that create the insulin.

Since Moniers diagnosis, his family has been involved with the foundation and has raised about $123,000 over the past nine years, said his mother, Kristy Monier.

Rory will travel to the nations capitol to participate in the Juvenile Diabetes Research Foundation Childrens Congress July 24-26. He was selected out of six applicants in Louisiana and more than 1,300 throughout the country.

-- Staff Writer Garrett Ohlmeyer can be reached at (985) 850-1149 or garrett.ohlmeyer@houmatoday.com. Follow him on Twitter @GOhlmeyer.

The rest is here:
Raceland boy to advocate diabetes research - Daily Comet

Read More...

Dow’s J&J Hosted A Diabetes Study And Lilly Will Benefit Most – Investor’s Business Daily

June 14th, 2017 12:48 am

Johnson & Johnson still faces troubles over its Invokana diabetes drug. (Kadmy-Fotolia/stock.adobe.com)

Johnson & Johnson's (JNJ) diabetes drug, Invokana, cut down on cardiovascular events during a long-termstudy but Eli Lilly (LLY) stands to benefit most asdoctors steer clear of the medication on worries it increased the risk of amputation.

The study, dubbed Canvas, was presented late Monday. In it, Dow stock Johnson & Johnson said Invokana reduced the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke by 14% vs. a non-drug placebo.

Additional analysis showed that Invokana lowered the risk of hospitalization for heart failure by 33%. Invokana also delayedthe progression of albuminuria the presence of a specific chemical in the urine indicating kidney disease.

RBC analyst Glenn Novarro says the Canvas study is unlikely to reverse the negative trajectory of Invokana sales. In the first quarter, Invokana and Invokamet sales dropped 17% year over year. For 2017, Novarro forecasts a 6% dip in sales to $1.2 billion.

Eli Lilly, on the other hand, will benefit from Johnson & Johnson's study as Merck (MRK) trails, analysts say.Lilly's Jardiance is a SGLT2 inhibitor, which works by helping the kidneys to lower blood glucose levels. Merck's Januvia is a DPP-4, which blocks glucagon release, triggering insulin secretion.

"Validated cardiovascular benefits should boost the SGLT2 class," Credit Suisse analyst Vamil Divan wrote. In a similar study, Lilly's Jardiance also showed a 14% benefit on cardiovascular outcomes. Jardiance also cut the risk of cardiovascular death and all mortality.

Even without the Canvas study, Lillywaspoised to grab a chunk of Invokana's sales after the Food and Drug Administration required Johnson & Johnson to warn physicians of the potential for amputation associated with Invokana.Invokana doubled the risk of amputation in a recent study.

Experts cited by Leerink analyst Seamus Fernandez say the amputation worry could be the "biggest differentiating factor" in physicians' decision to prescribe Jardiance over Invokana, as both show a similar cardiovascular benefit in diabetes patients.

At the close on the stock market today, Johnson & Johnson stock ticked up 0.2% to finish the regular trading session at 132.02. Lilly stock added 0.4% to 81.25 and shares of diabetes drugmaker Merck dipped 1% to end the day at 63.27.

IBD'S TAKE:Johnson & Johnson stock has an IBD Composite Rating of 77, meaning it outperforms more than three-quarters of all stocks in terms of key growth metrics. For more of IBD's ratings visit IBD Stock Checkup.

Meanwhile, the DPP-4 class of diabetes drugs, which includes Merck's Januvia, could face incremental pressure, Credit Suisse's Divan said.

"Over time, however, we expect the enthusiastic response to the Canvas efficacy data driving use of the SGLT2 class earlier in the course of treatment, while concurrently pushing the DPP-4s further back," he said in a note to clients.

Merck and Pfizer (PFE), a Dow stock, are jointly working on an SGLT2 inhibitor called ertugliflozin.Regulators could approve the drug in December, but it won't have data on cardiovascular outcomes for several years.Pfizer will take a chunk of thosesales, meaning a shift from Januvia toertugliflozin will be a net negative for Merck.

RELATED:

Lilly Could Grab Diabetes Share From Dow's J&J On Amputation Woes

AbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise

Dow's Pfizer Faces Challenges As Roche, J&J, Lilly Loom

4:38 PM ET Get the latest news and analysis on the Dow Jones Industrial Average and its 30 component stocks.

4:38 PM ET Get the latest news and analysis on the Dow Jones...

Original post:
Dow's J&J Hosted A Diabetes Study And Lilly Will Benefit Most - Investor's Business Daily

Read More...

Rabbi has warning after concluding reviving dead ‘clearly possible’ – WND.com

June 14th, 2017 12:45 am

El Grecos Resurrection

A rabbi has issued a warning after concluding that raising the dead is clearly possible.

Its not for man to do.

The comments come from Rabbi Moshe Avraham Halperin and were reported by Breaking Israel News.

If they are able to revive a person from total brain death, it will be considered techiyat hamaytim [resurrection], he told BIN. Torah laws puts limits on man, forbidding him from some areas which are strictly divine. Reviving the dead is one of them.

Further, another rabbi said such experiments never will succeed.

The Rambam states that we must believe that the resurrection of the dead will happen when it is Gods will for it to take place and at no other time, Rabbi Yosef Berger, of King Davids Tom on Mount Zion in Jerusalem, told the news agency.

Transhumanism: Recreating humanity reveals the secret ways scientists are using technologyto pursue immortality, omniscience and ultimate power. Now available in the WND Superstore.

He was citing the 13 Principles of Faith set down by Rabbi Moses ben Maimon, whose 12th century work established him as a Torah authority and gave him the acronym Rambam.

He stated, I believe by complete faith that there will be a resurrection of the dead at the time that will be pleasing before the Creator.

That, Berger suggested, means: Not only does this effort by scientists go against this principle of faith, but we know that true resurrection can only happen by Divine will. Resurrection of the dead is described in depth, and it is proof of Gods rule over the physical world. But it is also stated that before the Messiah, there is no return from the grave.

The comments come on the heels of plans by a biomedical company, Bioquark, a startup based in Pennsylvania, to experiment with stem cells in an attempt to revive brain-dead patients.

BIN reported the company said it would launch experiments before the end of the year on such patients.

The trial will involve a multi-pronged approach, involving injecting stem cells and peptides into the spinal cords, electrical nerve stimulation, and laser therapy. The researchers hope this will grow new neurons and spur them to connect to each other, bringing the brain back to life, BIN reported.

What do YOU think? Sound off on scientific efforts to revive dead people

The story pointed out that Bioquark reportedly tried such an experiment in India in 2016 but it was not with the approval of the nations drug regulators.

Amar Jesani, editor of the Indian Journal of Medical Ethics in Mumbai, cautioned that even partial success would traumatize families that had come to terms with a situation they believed irreversible. In point of fact, no families permitted their loved ones to be part of the experiment, BIN reported.

Halperin said, This is like using genetics to create a new form of life. There are realms that are strictly divine. Resurrection of the dead is clearly possible. It is definitely going to happen after the Messiah, but it restricted to God.

It was reported about a year ago that Bioquark and another company were embarking on the Reanima project, using a new drug formula involving stem cells.

Their plan was to use neurons, proteins, peptides and more that would create a microenvironment in which the stems cells can mature.

The report said, Inspired by organisms like salamanders that can regrow severed or damaged tails, Bioquark researchers have been developing regenerative treatments for a host of uses, from cancer to spinal cord injuries.

WND had reported when the company was given the green light on the visionary project.

The company said then it was capable of creating dynamics in mature tissues that are normally only seen during human fetal development, as well as during limb and organ regeneration in organisms like amphibians.

Christian author and filmmaker Tom Horn, at that time, said scientists are redefining what it means to be human, with the goal of transcending humanity.

Right here in North Carolina at your university, they have what is called a transgenic lab, which means they have mice that have human genetic material, for testing to see if the human parts in that animal are responding, he told TV host Sid Roth in a recent interview.

Using a gene-editing technique, one university lab cured cancer in a group of rats, but the unintended consequences were that the rats started aging very quickly and died at half-life, and nobody knows why that happened, Horn said. There is a danger in playing God because youre not God and you dont know.

Transhumanism: Recreating humanity reveals the secret ways scientists are using technologyto pursue immortality, omniscience and ultimate power. Now available in the WND Superstore.

See more here:
Rabbi has warning after concluding reviving dead 'clearly possible' - WND.com

Read More...

WATCH: Long Island Teen, 16, Cured from Blindness Earns Golden Buzzer on America’s Got Talent – PEOPLE.com

June 14th, 2017 12:45 am

Christian Guardino brushed off his nerves and blew audiences away with his powerful performance!

The 16-year-old boy from Long Island, New York earned the coveted Golden Buzzer from judge Howie Mandel on Tuesdays Americas Got Talent with a soulful rendition ofThe Jackson 5s 1969 single Whos Lovin You.

You were like a little mouse that turned into a lion. You are one of my favorite contestants Ive seen this year. Not only in terms of your voice. I just like you. Theres something about you, and its just the best possible feeling when we meet someone like you, Simon Cowell told Christian, who teared up on stage.

And when Mandell asked the singer if he could make one wish come true, Christian said: Probably the golden buzzer.

The Golden Buzzer puts Christian directly through to the hit NBC talent competitions upcoming live rounds.

On Tuesdays episode, Christian and his mother, Elizabeth, opened up about his journey of being blind for most of his life before an experimental treatment gave him back his sight.

Christian was diagnosed with a retinal disease called Leber congenital amaurosis (LCA), according to his September 2016 profile in National Geographic. He was cured of blindness after receivinggene therapy treatment andnow can see well enough to read enlarged notes on sheet music.

Christian has plenty of singing experience.He has previously performed four times at theApollo Theater in Harlem, New York.

Mandels Golden Buzzer recipient is the third one this season, following Mel Bs 12-year-old singing ventriloquist Darci Lynne Farmer and Cowells 29-year-old deaf singer Mandy Harvey. Judge Heidi Klum still has yet to select her Golden Buzzer contestant.

Americas Got Talent airs Tuesdays (8 p.m. ET) on NBC.

Read the rest here:
WATCH: Long Island Teen, 16, Cured from Blindness Earns Golden Buzzer on America's Got Talent - PEOPLE.com

Read More...

Despite blindness, Parkman successfully chronicled US history – White Mountain Independent

June 14th, 2017 12:45 am

In the 1800s, as today, people overcame challenges to make great accomplishments.

Although many people dont know who he is, the subject of this weeks story has been called our greatest American historian.

Francis Parkman was born in Boston in 1823. His grandfather was a wealthy merchant whose estate provided him with enough money to be a man of independent means.

In 1846, Francis graduated Phi Beta Kappa from Harvard. After graduation, he became intrigued with the French and Indian Wars from 1689 to 1763, and decided to write a book. For background material, he felt it was necessary to get a picture of the Indian before the arrival of the Europeans.

Realizing he was no longer able to do that with the northeastern Indians, Francis headed west. On June 15, 1846, he arrived at Fort Laramie, Wyo. Over the next six months, he lived with the Oglala Sioux and discovered these blood-thirsty savages were actually a warm and generous people who indulged their children to excess and were devoid of greed. The result was an important book about the ethnicity of the Indian titled, The Oregon Trail.

Because of an illness that plagued him throughout his life, he had to return east after six months. In a short time, Francis became virtually blind, making it impossible for him to see what he wrote. He had to use a device called a noctograph that had spaced wires so he could write on a straight line. For five years, he couldn't concentrate for more than a few minutes at a time.

In spite of these handicaps, Francis Parkman's passion for chronicling the true history of the United States kept him working. During his life, he wrote more than 30 books and is considered one of our great writers.

Dakota Livesay is the editor of the Chronicle of the Old West. For more information about the Old West visit http://www.ChronicleoftheOldWest.com. You can hear Dakota at 10 a.m. each day on KZUZ 93.5 in Show Low and KZUA 92.1 in Holbrook.

See the original post:
Despite blindness, Parkman successfully chronicled US history - White Mountain Independent

Read More...

Biotechnology FAQs | USDA

June 14th, 2017 12:44 am

1. What is Agricultural Biotechnology?

Agricultural biotechnology is a range of tools, including traditional breeding techniques, that alter living organisms, or parts of organisms, to make or modify products; improve plants or animals; or develop microorganisms for specific agricultural uses. Modern biotechnology today includes the tools of genetic engineering.

2. How is Agricultural Biotechnology being used?

Biotechnology provides farmers with tools that can make production cheaper and more manageable. For example, some biotechnology crops can be engineered to tolerate specific herbicides, which make weed control simpler and more efficient. Other crops have been engineered to be resistant to specific plant diseases and insect pests, which can make pest control more reliable and effective, and/or can decrease the use of synthetic pesticides. These crop production options can help countries keep pace with demands for food while reducing production costs. A number of biotechnology-derived crops that have been deregulated by the USDA and reviewed for food safety by the Food and Drug Administration (FDA) and/or the Environmental Protection Agency (EPA) have been adopted by growers.

Many other types of crops are now in the research and development stages. While it is not possible to know exactly which will come to fruition, certainly biotechnology will have highly varied uses for agriculture in the future. Advances in biotechnology may provide consumers with foods that are nutritionally-enriched or longer-lasting, or that contain lower levels of certain naturally occurring toxicants present in some food plants. Developers are using biotechnology to try to reduce saturated fats in cooking oils, reduce allergens in foods, and increase disease-fighting nutrients in foods. They are also researching ways to use genetically engineered crops in the production of new medicines, which may lead to a new plant-made pharmaceutical industry that could reduce the costs of production using a sustainable resource.

Genetically engineered plants are also being developed for a purpose known as phytoremediation in which the plants detoxify pollutants in the soil or absorb and accumulate polluting substances out of the soil so that the plants may be harvested and disposed of safely. In either case the result is improved soil quality at a polluted site. Biotechnology may also be used to conserve natural resources, enable animals to more effectively use nutrients present in feed, decrease nutrient runoff into rivers and bays, and help meet the increasing world food and land demands. Researchers are at work to produce hardier crops that will flourish in even the harshest environments and that will require less fuel, labor, fertilizer, and water, helping to decrease the pressures on land and wildlife habitats.

In addition to genetically engineered crops, biotechnology has helped make other improvements in agriculture not involving plants. Examples of such advances include making antibiotic production more efficient through microbial fermentation and producing new animal vaccines through genetic engineering for diseases such as foot and mouth disease and rabies.

3. What are the benefits of Agricultural Biotechnology?

The application of biotechnology in agriculture has resulted in benefits to farmers, producers, and consumers. Biotechnology has helped to make both insect pest control and weed management safer and easier while safeguarding crops against disease.

For example, genetically engineered insect-resistant cotton has allowed for a significant reduction in the use of persistent, synthetic pesticides that may contaminate groundwater and the environment.

In terms of improved weed control, herbicide-tolerant soybeans, cotton, and corn enable the use of reduced-risk herbicides that break down more quickly in soil and are non-toxic to wildlife and humans. Herbicide-tolerant crops are particularly compatible with no-till or reduced tillage agriculture systems that help preserve topsoil from erosion.

Agricultural biotechnology has been used to protect crops from devastating diseases. The papaya ringspot virus threatened to derail the Hawaiian papaya industry until papayas resistant to the disease were developed through genetic engineering. This saved the U.S. papaya industry. Research on potatoes, squash, tomatoes, and other crops continues in a similar manner to provide resistance to viral diseases that otherwise are very difficult to control.

Biotech crops can make farming more profitable by increasing crop quality and may in some cases increase yields. The use of some of these crops can simplify work and improve safety for farmers. This allows farmers to spend less of their time managing their crops and more time on other profitable activities.

Biotech crops may provide enhanced quality traits such as increased levels of beta-carotene in rice to aid in reducing vitamin A deficiencies and improved oil compositions in canola, soybean, and corn. Crops with the ability to grow in salty soils or better withstand drought conditions are also in the works and the first such products are just entering the marketplace. Such innovations may be increasingly important in adapting to or in some cases helping to mitigate the effects of climate change.

The tools of agricultural biotechnology have been invaluable for researchers in helping to understand the basic biology of living organisms. For example, scientists have identified the complete genetic structure of several strains of Listeria and Campylobacter, the bacteria often responsible for major outbreaks of food-borne illness in people. This genetic information is providing a wealth of opportunities that help researchers improve the safety of our food supply. The tools of biotechnology have "unlocked doors" and are also helping in the development of improved animal and plant varieties, both those produced by conventional means as well as those produced through genetic engineering.

4. What are the safety considerations with Agricultural Biotechnology?

Breeders have been evaluating new products developed through agricultural biotechnology for centuries. In addition to these efforts, the United States Department of Agriculture (USDA), the Environmental Protection Agency (EPA), and the Food and Drug Administration (FDA) work to ensure that crops produced through genetic engineering for commercial use are properly tested and studied to make sure they pose no significant risk to consumers or the environment.

Crops produced through genetic engineering are the only ones formally reviewed to assess the potential for transfer of novel traits to wild relatives. When new traits are genetically engineered into a crop, the new plants are evaluated to ensure that they do not have characteristics of weeds. Where biotech crops are grown in proximity to related plants, the potential for the two plants to exchange traits via pollen must be evaluated before release. Crop plants of all kinds can exchange traits with their close wild relatives (which may be weeds or wildflowers) when they are in proximity. In the case of biotech-derived crops, the EPA and USDA perform risk assessments to evaluate this possibility and minimize potential harmful consequences, if any.

Other potential risks considered in the assessment of genetically engineered organisms include any environmental effects on birds, mammals, insects, worms, and other organisms, especially in the case of insect or disease resistance traits. This is why the USDA's Animal and Plant Health Inspection Service (APHIS) and the EPA review any environmental impacts of such pest-resistant biotechnology derived crops prior to approval of field-testing and commercial release. Testing on many types of organisms such as honeybees, other beneficial insects, earthworms, and fish is performed to ensure that there are no unintended consequences associated with these crops.

With respect to food safety, when new traits introduced to biotech-derived plants are examined by the EPA and the FDA, the proteins produced by these traits are studied for their potential toxicity and potential to cause an allergic response. Tests designed to examine the heat and digestive stability of these proteins, as well as their similarity to known allergenic proteins, are completed prior to entry into the food or feed supply. To put these considerations in perspective, it is useful to note that while the particular biotech traits being used are often new to crops in that they often do not come from plants (many are from bacteria and viruses), the same basic types of traits often can be found naturally in most plants. These basic traits, like insect and disease resistance, have allowed plants to survive and evolve over time.

5. How widely used are biotechnology crops?

According to the USDA's National Agricultural Statistics Service (NASS), biotechnology plantings as a percentage of total crop plantings in the United States in 2012 were about 88 percent for corn, 94 percent for cotton, and 93 percent for soybeans. NASS conducts an agricultural survey in all states in June of each year. The report issued from the survey contains a section specific to the major biotechnology derived field crops and provides additional detail on biotechnology plantings. The most recent report may be viewed at the following website: https://www.ers.usda.gov/data-products/adoption-of-genetically-engineered-crops-in-the-us.aspx

For a summary of these data, see the USDA Economic Research Service data feature at: https://www.ers.usda.gov/data-products/adoption-of-genetically-engineered-crops-in-the-us.aspx

The USDA does not maintain data on international usage of genetically engineered crops. The independent International Service for the Acquisition of Agri-biotech Applications (ISAAA), a not-for-profit organization, estimates that the global area of biotech crops for 2012 was 170.3 million hectares, grown by 17.3 million farmers in 28 countries, with an average annual growth in area cultivated of around 6 percent. More than 90 percent of farmers growing biotech crops are resource-poor farmers in developing countries. ISAAA reports various statistics on the global adoption and plantings of biotechnology derived crops. The ISAAA website is https://www.isaaa.org

6. What are the roles of government in agricultural biotechnology?

Please note: These descriptions are not a complete or thorough review of all the activities of these agencies with respect to agricultural biotechnology and are intended as general introductory materials only. For additional information please see the relevant agency websites.

Regulatory

The Federal Government developed a Coordinated Framework for the Regulation of Biotechnology in 1986 to provide for the regulatory oversight of organisms derived through genetic engineering. The three principal agencies that have provided primary guidance to the experimental testing, approval, and eventual commercial release of these organisms to date are the USDA's Animal and Plant Health Inspection Service (APHIS), the Environmental Protection Agency (EPA), and the Department of Health and Human Services' Food and Drug Administration (FDA). The approach taken in the Coordinated Framework is grounded in the judgment of the National Academy of Sciences that the potential risks associated with these organisms fall into the same general categories as those created by traditionally bred organisms.

Products are regulated according to their intended use, with some products being regulated under more than one agency. All government regulatory agencies have a responsibility to ensure that the implementation of regulatory decisions, including approval of field tests and eventual deregulation of approved biotech crops, does not adversely impact human health or the environment.

The Animal and Plant Health Inspection Service (APHIS) is responsible for protecting U.S. agriculture from pests and diseases. APHIS regulations provide procedures for obtaining a permit or for providing notification prior to "introducing" (the act of introducing includes any movement into or through the U.S., or release into the environment outside an area of physical confinement) a regulated article in the U.S. Regulated articles are organisms and products altered or produced through genetic engineering that are plant pests or for which there is reason to believe are plant pests.

The regulations also provide for a petition process for the determination of non-regulated status. Once a determination of non-regulated status has been made, the organism (and its offspring) no longer requires APHIS review for movement or release in the U.S.

For more information on the regulatory responsibilities of the FDA, the EPA and APHIS please see:

https://www.fda.gov

https://www.epa.gov

APHIS Biotechnology Regulations

Market Facilitation

The USDA also helps industry respond to consumer demands in the United States and overseas by supporting the marketing of a wide range of agricultural products produced through conventional, organic, and genetically engineered means.

The Agricultural Marketing Service (AMS) and the Grain Inspection, Packers, and Stockyards Administration (GIPSA) have developed a number of services to facilitate the strategic marketing of conventional and genetically engineered foods, fibers, grains, and oilseeds in both domestic and international markets. GIPSA provides these services for the bulk grain and oilseed markets while AMS provides the services for food commodities such as fruits and vegetables, as well as for fiber commodities.

These services include:

1. Evaluation of Test Kits: AMS and GIPSA evaluate commercially available test kits designed to detect the presence of specific proteins in genetically engineered agricultural commodities. The agencies confirm whether the tests operate in accordance with manufacturers' claims and, if the kits operate as stated, the results are made available to the public on their respective websites.

GIPSA Link: https://www.gipsa.usda.gov/fgis/rapidtestkit.aspx

GIPSA evaluates the performance of laboratories conducting DNA-based tests to detect genetically engineered grains and oilseeds, provides participants with their individual results, and posts a summary report on the GIPSA website. AMS is developing a similar program that can evaluate and verify the capabilities of independent laboratories to screen other products for the presence of genetically engineered material.

2. Identity Preservation/Process Verification Services: AMS and GIPSA offer auditing services to certify the use of written quality practices and/or production processes by producers who differentiate their commodities using identity preservation, testing, and product branding.

GIPSA Link: https://www.gipsa.usda.gov/fgis/inspectionweighing.aspx

AMS Link: https://www.ams.usda.gov/fv/ipbv.htm

Additional AMS Services: AMS provides fee-based DNA and protein testing services for food and fiber products, and its Plant Variety Protection Office offers intellectual property rights protection for new genetically engineered seed varieties through the issuance of Certificates of Protection.

Additional GIPSA Services: GIPSA provides marketing documents pertaining to whether there are genetically engineered varieties of certain bulk commodities in commercial production in the United States. USDA also works to improve and expand market access for U.S. agricultural products, including those produced through genetic engineering.

The Foreign Agricultural Service (FAS) supports or administers numerous education, outreach, and exchange programs designed to improve the understanding and acceptance of genetically engineered agricultural products worldwide

1. Market Access Program and Foreign Market Development Program: Supports U.S. farm producer groups (called "Cooperators") to market agricultural products overseas, including those produced using genetic engineering.

2. Emerging Markets Program: Supports technical assistance activities to promote exports of U.S. agricultural commodities and products to emerging markets, including those produced using genetic engineering. Activities to support science-based decision-making are also undertaken. Such activities have included food safety training in Mexico, a biotechnology course for emerging market participants at Michigan State University, farmer-to-farmer workshops in the Philippines and Honduras, high-level policy discussions within the Asia-Pacific Economic Cooperation group, as well as numerous study tours and workshops involving journalists, regulators, and policy-makers.

3. Cochran Fellowship Program: Supports short-term training in biotechnology and genetic engineering. Since the program was created in 1984, the Cochran Fellowship Program has provided education and training to 325 international participants, primarily regulators, policy makers, and scientists.

4. Borlaug Fellowship Program: Supports collaborative research in new technologies, including biotechnology and genetic engineering. Since the program was established in 2004, the Borlaug Fellowship Program has funded 193 fellowships in this research area.

5. Technical Assistance for Specialty Crops (TASC): Supports technical assistance activities that address sanitary, phytosanitary, and technical barriers that prohibit or threaten the export of U.S. specialty crops. This program has supported activities on biotech papaya.

Research

USDA researchers seek to solve major agricultural problems and to better understand the basic biology of agriculture. Researchers may use biotechnology to conduct research more efficiently and to discover things that may not be possible by more conventional means. This includes introducing new or improved traits in plants, animals, and microorganisms and creating new biotechnology-based products such as more effective diagnostic tests, improved vaccines, and better antibiotics. Any USDA research involving the development of new biotechnology products includes biosafety analysis.

USDA scientists are also improving biotechnology tools for ever safer, more effective use of biotechnology by all researchers. For example, better models are being developed to evaluate genetically engineered organisms and to reduce allergens in foods.

USDA researchers monitor for potential environmental problems such as insect pests becoming resistant to Bt, a substance that certain crops, such as corn and cotton, have been genetically engineered to produce to protect against insect damage. In addition, in partnership with the Agricultural Research Service (ARS) and the Forest Service, the Cooperative States Research, the National Institute of Food and Agriculture (NIFA) administers the Biotechnology Risk Assessment Research Grants Program (BRAG) which develops science-based information regarding the safety of introducing genetically engineered plants, animals, and microorganisms. Lists of biotechnology research projects can be found at https://www.ars.usda.gov/research/projects.htm for ARS and at https://www.nifa.usda.gov/funding-opportunity/biotechnology-risk-assessment-research-grants-program-brag for NIFA.

USDA also develops and supports centralized websites that provide access to genetic resources and genomic information about agricultural species. Making these databases easily accessible is crucial for researchers around the world.

USDA's National Institute of Food and Agriculture (NIFA) provides funding and program leadership for extramural research, higher education, and extension activities in food and agricultural biotechnology. NIFA administers and manages funds for biotechnology through a variety of competitive and cooperative grants programs. The National Research Initiative (NRI) Competitive Grants Program, the largest NIFA competitive program, supports basic and applied research projects and integrated research, education, and/or extension projects, many of which use or develop biotechnology tools, approaches, and products. The Small Business Innovation Research Program (SBIR) funds competitive grants to support research by qualified small businesses on advanced concepts related to scientific problems and opportunities in agriculture, including development of biotechnology-derived products. NIFA also supports research involving biotechnology and biotechnology-derived products through cooperative funding programs in conjunction with state agricultural experiment stations at land-grant universities. NIFA partners with other federal agencies through interagency competitive grant programs to fund agricultural and food research that uses or develops biotechnology and biotechnology tools such as metabolic engineering, microbial genome sequencing, and maize genome sequencing.

USDA's Economic Research Service (ERS) conducts research on the economic aspects of the use of genetically engineered organisms, including the rate of and reasons for adoption of biotechnology by farmers. ERS also addresses economic issues related to the marketing, labeling, and trading of biotechnology-derived products.

Read the original post:
Biotechnology FAQs | USDA

Read More...

iShares Nasdaq Biotechnology Index Fund (IBB) Stock Rating Upgraded by Vetr Inc. – The Cerbat Gem

June 14th, 2017 12:44 am
iShares Nasdaq Biotechnology Index Fund (IBB) Stock Rating Upgraded by Vetr Inc.
The Cerbat Gem
iShares Nasdaq Biotechnology Index Fund logo Vetr upgraded shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) from a hold rating to a buy rating in a report issued on Wednesday, May 17th. They currently have $303.00 target price on the ...
The iShares NASDAQ Biotechnology Index (IBB) Position Boosted ...BangaloreWeekly
iShares Nasdaq Biotechnology Index Fund (IBB) Position ...BBNS
iShares Nasdaq Biotechnology Index Fund (IBB) Position Raised by Pinnacle Associates Ltd.Transcript Daily
Chaffey Breeze -Stock Observer
all 11 news articles »

See original here:
iShares Nasdaq Biotechnology Index Fund (IBB) Stock Rating Upgraded by Vetr Inc. - The Cerbat Gem

Read More...

Cool’ New Knee Procedure Eases Arthritis Pain Without Surgery – NBCNews.com

June 14th, 2017 12:44 am

A new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.

The treatment, recently approved by the Food and Drug Administration, is called cooled radio frequency ablation and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that dont make them a good candidate for surgery.

Marketed as "Coolief", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain. Coolief doesnt repair arthritis in the knee, but eases the pain, helping patients go back to activities without discomfort and fewer medications.

What we're changing is the wiring of the knee so we're taking away the pain signal and interrupting it," Dr. Amin Sandeep, a pain specialist at Rush University Medical Center in Chicago who performs the procedure, told NBC News.

One 2016 study compared Coolief to popular cortisone injections, with patients reporting greater, longer-lasting pain relief with the new treatment than injections. Coolief reduces pain for about to 6 to 12 months, depending on how fast the nerves in the knee regenerate.

Related: Common Knee Surgery May Not Help You

Osteoarthritis can affect any joint when the cartilage wears off over time, often striking big joints like the knee, causing pain, swelling and stiffness. According to the American Academy of Orthopedic Surgeons, nearly 10 million Americans had osteoarthritis of the knee in 2010.

The three current recommended approaches for knee arthritis pain are physical therapy, non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, or the opioid painkiller tramadol.

But those didn't help Felicia McCloden, a 65-year-old grandmother from outside of Chicago. The excruciating pain in her right knee made simple tasks like grocery shopping impossible.

I had inflammation, swelling, and my knee was like the size of a golf ball, McCloden told NBC News. "The arthritis was so bad that I could barely step down without severe pain.

Because she wasnt eligible for a knee replacement she tried cortisone injections, physical therapy, medications nothing relieved her pain.

"I thought I was going to limp for the rest of my life," she said.

Related: What Really Helps Knee Pain? The Answer May Surprise You

In May, McCloden underwent the Coolief treatment and the result was instant.

I couldn't even imagine first of all, not having the pain," she said. "It erased all of that.

The outpatient procedure typically takes about 40 minutes, is performed with local anesthesia and doesnt require an incision. Instead, doctors use specialized needles that emit radio frequencywaves into the knee. The cost of the treatment is between $2,000 and $4,000. Because it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.

Some of the reported risks from the procedure include bleeding and infection. "Though patients have a risk of the physician hitting the wrong nerve, that is extremely rare in the hands of an experienced professional, Amin said.

Recovery time is minimal, with most patients walking immediately after the procedure and resuming normal activities in a day or two.

For some patients with structural problems of the knee, the procedure won't help, said pain specialist Dr. Edgar Ross, associate professor of anesthesia at Brigham and Womens Hospital.

"But lets say a patient is younger, instead of going for a total knee replacement early, which might have to be repeated later on, Coolief can postpone the need for the total knee replacement," Ross told NBC News.

Coolief can be repeated if necessary, but it's not a permanent solution. While it reduces pain, it can't stop the progression of osteoarthritis.

"While it can delay total knee replacement, knee replacement may still eventually be necessary in a big number of patients," said Dr. Dennis Cardone, associate professor of orthopedic surgery at NYU Langone Medical Center.

Link:
Cool' New Knee Procedure Eases Arthritis Pain Without Surgery - NBCNews.com

Read More...

Diet to cure arthritis: Eating THIS part of the Mediterranean diet could suppress symptoms – Express.co.uk

June 14th, 2017 12:44 am

GETTY

It affects more than 690,000 people in the UK, of which over 500,000 are women and around three-quarters are of working age.

Experts believe the Mediterranean diet is effective in suppressing rheumatoid arthritis - but the elements responsible for this currently remain unknown.

Now researchers from Osaka City University in Japan, have set out to investigate what part of the diet - which constitutes oily fish, olive oil, fruit and vegetables - could help ease symptoms of the disease.

A study looked at 208 patients with rheumatoid arthritis and 205 healthy volunteers from the same age group.

GETTY

Their food and nutrient intake was assessed using a questionnaire, a Mediterranean diet score was calculated and the prevalence of the disease in 28 joints was analysed.

Experts found the consumption of MUFA - monosaturated fatty acids, alcohol, pulses, vegetables, meat milk and dairy products were significantly lower among participants with RA.

The study authors said: Intake of monounsaturated fatty acids (MUFA) was significantly lower in the RA, than in the control group (P=0.003) and the ratio of consumed monounsaturated to saturated fatty acid significantly differed within the RA group.

What are monosaturated fats?

Monounsaturated fats can help reduce levels of bad cholesterol in the blood - reducing the risk of heart disease and stroke. Examples of foods which are high in monounsaturated fats include olive oil, sesame oil, avocados, peanut butter and nuts and seeds.

Getty

1 of 12

GETTY

Daily MUFA intake, a component of the Mediterranean diet score, might suppress disease activity in rheumatoid arthritis patients

Experts have also revealed eating a diet high in monounsaturated fats can reduce belly fat and encourage weight loss.

The study concluded: Daily MUFA intake, a component of the Mediterranean diet score, might suppress disease activity in RA patients.

People with rheumatoid arthritis experience a range of symptoms, including pain and swelling in the joints, tiredness and depression which can affect their daily lives, from their ability to do basic everyday tasks like buttoning a shirt, to the possibility of having to stop work as a result of their condition.

The study was published in the journal Clinical Nutrition.

Experts, writing in The Lancet Diabetes and Endocrinology last year said eating a Mediterranean diet with no limit on calories and plenty of olive oil is the best way to stay healthy.

Researchers said guidelines promoting low-fat, low-calorie diets had created an unnecessary fear of the fats present in food loved by the southern Europeans.

The study looked at more than 7,000 participants who were either given an unrestricted Mediterranean diet or a low-fat diet where the advice was to avoid all dietary fat.

On average, those in all groups lost some weight with the greatest loss seen in the group eating the Mediterranean diet with olive oil.

Dr Aseem Malhotra, cardiologist advisor to the National Obesity Forum, said: A high fat Mediterranean diet which I follow and tell my patients to not only doesnt lead to weight gain but is also the most protective dietary pattern against heart disease, cancer and dementia.

Read the original post:
Diet to cure arthritis: Eating THIS part of the Mediterranean diet could suppress symptoms - Express.co.uk

Read More...

Watch: Chiefs’ Charcandrick West sings to raise awareness for childhood arthritis – Kansas City Star

June 14th, 2017 12:44 am

Kansas City Star
Watch: Chiefs' Charcandrick West sings to raise awareness for childhood arthritis
Kansas City Star
Chiefs' running back Charcandrick West has a busy summer ahead as he battles for positioning on the depth chart. But West, who was diagnosed with arthritis at 14 years old, realizes life goes beyond football. So before organized team activities began ...

Continue reading here:
Watch: Chiefs' Charcandrick West sings to raise awareness for childhood arthritis - Kansas City Star

Read More...

Page 986«..1020..985986987988..1,0001,010..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick